Adverse effects of COVID-19 vaccination in patients with Transfusion Dependent Thalassemia (TDT): an observational study from a tertiary care centre in Punjab, India.

Vaccination against SARS-CoV2 is the most important weapon in the arsenal in the battle against COVID-19. There is concern about an increased risk of adverse effects in patients with transfusion-dependent thalassemia (TDT), which affects vaccine acceptance. A predesigned questionnaire was used to evaluate adverse effects (local/systemic within 90 days after vaccination) in participants >18 years of age with TDT. A total of 100 patients received 129 vaccine doses. The mean age of the patients was 24.3 ± 5.7 years and M: F ratio of 1.6:1. Covishield (Serum Institute of India) was administered to 89% of the participants and Covaxin (Bharat Biotech Limited) to 11% of the participants. Adverse effects were documented in 62% of the respondents and were more pronounced after the first dose (52%) compared to the second dose (9%). The most frequent adverse effects were pain at the injection site (43%) and fever (37%). All adverse effects were mild and none of the participants required hospitalization. There were no differences in adverse effects among different vaccines, the presence or absence of comorbidities, blood groups, or ferritin levels. The SARS-CoV2 vaccine appears to be safe in patients with TDT.